Norspan (Buprenorphine)

Buprenorphine, the active ingredient in Norspan, is an opioid analgesic presented as a 5‑20 µg/hour transdermal patch for transdermal use. The patch delivers continuous low‑dose buprenorphine over several days, providing analgesia for chronic moderate to severe pain, including cancer‑related pain, in adult patients.

GNH USA supplies Norspan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, ensuring quality‑controlled sourcing for the EU market and other regions. The company adheres to EU pharmacovigilance standards and provides logistics support for timely delivery.

Buprenorphine is an opioid analgesic used to manage pain that requires continuous opioid therapy. - Chronic non‑cancer pain: provides continuous opioid analgesia for patients requiring long‑term management. - Cancer‑related pain: offers sustained relief for moderate to severe pain associated with malignancy. - Severe chronic pain requiring opioid rotation: serves as an alternative when other opioids are ineffective or not tolerated.

Buprenorphine transdermal therapy can be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Application site erythema: redness at the patch site. - Pruritus: itching around the application area. - Nausea: feeling of queasiness. - Constipation: reduced bowel movements. - Dizziness: light‑headed sensation. - Headache: mild to moderate pain in the head.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing, potentially life‑threatening. - Severe hypotension: marked drop in blood pressure. - Cardiac arrhythmias (e.g., QT prolongation): abnormal heart rhythm that may lead to serious complications.

When prescribing Norspan, clinicians should consider several safety measures. - Assess opioid tolerance: confirm the patient has prior opioid exposure before initiating. - Monitor for respiratory depression: especially during dose escalation or in opioid‑naïve patients. - Avoid abrupt discontinuation: taper to prevent withdrawal symptoms. - Use with caution in hepatic impairment: dose may need adjustment. - Avoid in patients with known hypersensitivity to buprenorphine or patch components. - Store at room temperature (below 30 °C): keep in the original pouch, protect from light and moisture.

Buprenorphine may interact with other medicines, requiring careful review.

Major Interactions (Avoid): - Concomitant full opioid agonists (e.g., morphine, fentanyl): risk of additive respiratory depression. - Benzodiazepines or other CNS depressants: increased sedation and respiratory risk. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce buprenorphine plasma levels. - Monoamine oxidase inhibitors: potential for severe hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase buprenorphine exposure. - Alcohol: can enhance central nervous system depression. - Anticholinergic agents: may worsen constipation associated with opioid therapy.